Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Investigating the effects of HIF-2 inhibition on a clear cell renal cell carcinoma model

FY 2024-25

Summary
Kidney cancer is estimated to be the eighth most common cancer affecting Canadians in 2024. Although there have been major improvements in the treatments used to help individuals, there is still a need for more treatment options when the cancer spreads to areas of the body beyond the kidneys in a process called metastasis. When this happens, the outcomes of this disease become significantly worse for patients. As a result of this, it is important to better understand how this occurs and why the cancer develops, in order to help patients who are suffering from this disease and to help those who develop this disease in the future. To address this, we have collaborated with other laboratories to develop a model of cancer cells to better understand the processes that occur in a specific type of cancer affecting the kidneys called clear cell renal cell carcinoma, which represents more than a majority of kidney cancer cases. This would allow us to test a novel cancer therapy in order to see what happens to the cancer cells. We would then make comparisons with cells that were not treated with the therapy, which could help us determine what is involved in driving the development of this disease. As a result, we anticipate that these investigations will help to show that the model that was developed can be used as a platform to investigate clear cell renal cell carcinoma, as well as helping to find possible new targets for cancer therapies. This would help to assist researchers studying the disease, and it may potentially help patients in the future from the discovery of new cancer treatments.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
518335
Name
Huang Richard
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the effects of HIF-2 inhibition on a clear cell renal cell carcinoma model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therapeutics; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Metastasis; Single-Cell Rna Sequencing; Von Hippel-Lindau (Vhl) Disease
Abstract
Kidney cancer is estimated to be the eighth most common cancer affecting Canadians in 2024. Although there have been major improvements in the treatments used to help individuals, there is still a need for more treatment options when the cancer spreads to areas of the body beyond the kidneys in a process called metastasis. When this happens, the outcomes of this disease become significantly worse for patients. As a result of this, it is important to better understand how this occurs and why the cancer develops, in order to help patients who are suffering from this disease and to help those who develop this disease in the future. To address this, we have collaborated with other laboratories to develop a model of cancer cells to better understand the processes that occur in a specific type of cancer affecting the kidneys called clear cell renal cell carcinoma, which represents more than a majority of kidney cancer cases. This would allow us to test a novel cancer therapy in order to see what happens to the cancer cells. We would then make comparisons with cells that were not treated with the therapy, which could help us determine what is involved in driving the development of this disease. As a result, we anticipate that these investigations will help to show that the model that was developed can be used as a platform to investigate clear cell renal cell carcinoma, as well as helping to find possible new targets for cancer therapies. This would help to assist researchers studying the disease, and it may potentially help patients in the future from the discovery of new cancer treatments.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Huang, Richard
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~